Antibacterials as anti-inflammatory agents: Dual action agents for oral health

Antonie van Leeuwenhoek, International Journal of General and Molecular Microbiology

Volumn 93, Issue 3, 2008, Pages 227-239

  Sreenivasan, Prem K ^a   Gaffar, Abdul ^a,b  

^a Oral Care Research and Development   (United States)

^b NONE   (United States)

Author keywords

Antibiotics; Antimicrobial; Clinical trials; Cyclines; Cytokines; Dentifrice; Gingivitis; Inflammation; Macrolides; Phenolics; Plaque; Tetracycline; Triclosan

Indexed keywords

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ARACHIDONATE 5 LIPOXYGENASE; ARESTIN; ATRIDOX; BATIMASTAT; CC 10232; CHLORHEXIDINE; CIPEMASTAT; COLLAGENASE INHIBITOR; CYCLINE DERIVATIVE; DISODIUM 6,6' [CARBONYL BIS(IMINO 3,1 PHENYLENECARBONYLIMINO)]BIS [4 HYDROXY 2 NAPTHALENESULFONATE]; DODECYL SULFATE SODIUM; DOXYCYCLINE; ERYTHROMYCIN; EUGENOL; FLUORIDE SODIUM; FUSAFUNGINE; MACROLIDE; MARIMASTAT; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYBENZONE; PHENOL DERIVATIVE; POLYSORBATE 80; PROSTAGLANDIN SYNTHASE; TAUROLINE; TETRACYCLINE; THYMOL; TOOTHPASTE; TRICLOSAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTINOBACTERIA; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DENTAL CARIES; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; GINGIVITIS; GRAM NEGATIVE BACTERIUM; HALITOSIS; HOST PATHOGEN INTERACTION; HUMAN; IC 50; IMMUNOMODULATION; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MOUTH DISEASE; MOUTH HYGIENE; NONHUMAN; PATHOPHYSIOLOGY; PERIODONTITIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STREPTOCOCCUS; TOOTH BRUSHING; TOOTH PLAQUE;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GINGIVITIS; HUMANS; ORAL HEALTH;

EID: 38649107023     PISSN: 00036072     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10482-007-9197-8     Document Type: Review

References (70)

1. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783-801
2. Allon M (2004) Dialysis catheter-related bacteremia: Treatment and prophylaxis. Am J Kidney Dis 44:779-791
3. Amsden GW (2005) Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 55:10-21
4. Bagley DM, Lin YJ (2000) Clinical evidence for the lack of triclosan accumulation from daily use in dentifrices. Am J Dent 13:148-152
5. Barkvoll P, Rolla G (1994) Triclosan protects the skin against dermatitis caused by sodium lauryl sulphate exposure. J Clin Periodontol 21:717-719
6. Barkvoll P, Rolla G (1995) Triclosan reduces the clinical symptoms of the allergic patch test reaction (APR) elicited with 1% nickel sulphate in sensitised patients. J Clin Periodontol 22:485-487
7. Bedrosian I, Sofia RD, Wolff SM, Dinarello CA (1991) Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. Cytokine. 3:568-575
8. Braumann C, Stuhldreier B, Bobrich E, Menenakos C, Rogalla S, Jacobi CA (2005) High doses of taurolidine inhibit advanced intraperitoneal tumor growth in rats. J Surg Res 129:129-135
9. Brett PM, Zygogianni P, Griffiths GS, Tomaz M, Parkar M, D'Aiuto F, Tonetti M (2005) Functional gene polymorphisms in aggressive and chronic periodontitis. J Dent Res 84:1149-1153
10. Ciancio SG. (2007) Improving our patients' oral health: The role of a triclosan/copolymer/fluoride dentifrice. Compend Contin Educ Dent 28:178-180, 182-183
11. Ciancio SG, Golub LM, Mather ML, Bunnell H (1985) The application of a collagen stabilizer to the gingia of the beagle dog. Effect of ligature-induced periodontal disease. J Periodontol 56:148-153
12. Close DR (2001) Matrix metalloproteinase inhibitors in rheumatic diseases. Ann Rheum Dis 60(Suppl 3):62-67
13. Davies RM, Ellwood RP, Davies GM (2004) The effectiveness of a toothpaste containing triclosan and polyvinyl-methyl ether maleic acid copolymer in improving plaque control and gingival health: A systematic review. J Clin Periodontol 31:1029-1033
14. DeVizio W, Davies R (2004) Rationale for the daily use of a dentifrice containing triclosan in the maintenance of oral health. Compend Contin Educ Dent 25(7 Suppl 1): 54-57
15. Dewhirst FE (1980) Structure-activity relationships for inhibition of prostaglandin cyclooxygenase by phenolic compounds. Prostaglandins 20:209-222
16. Dixon DR, Bainbridge BW, Darveau RP (2004) Modulation of the innate immune response within the periodontium. Periodontology 2000 35:53-74
17. Ezzo PJ, Cutler CW (2003) Microorganisms as risk indicators for periodontal disease. Periodontol 2000 32:24-35
18. Fernandes P (2006) Antibacterial discovery and development-the failure of success? Nat Biotechnol 24:1497-1503
19. Gaffar A, (2001) Oral care products. In: Barel AO, Paye M, Maibach HI (eds) Handbook of cosmetic science and technology, 2nd edn. Marcel Dekker, New York, pp 619-643
20. German-Fattal M, Mosges R (2004) How to improve current therapeutic standards in upper respiratory infections: Value of fusafungine. Curr Med Res Opinion 20:1769-1776
21. Golub LM, Payne JB, Reinhardt RA, Nieman G (2006) Can systemic diseases co-induce (not just exacerbate) periodontitis? A hypothetical "two-hit" model. J Dent Res 85:102-105
22. Gunsolley JC (2006) A meta-analysis of six-month studies of antiplaque and antigingivitis agents. J Am Dent Assoc 137:1649-1657
23. Hioe KP, van der Weijden GA (2005) The effectiveness of self-performed mechanical plaque control with triclosan containing dentifrices. Int J Dent Hyg 3:192-204
24. Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombola L, Carnuccio R, Iuvone T, D'Acquisto F, Di Rosa M (2000) Anti-inflammaory activity of macrolide antibiotics. J Pharmacol Experiment Ther 292:156-163
25. Jannesson L, Birkhed D, Scherl D, Gaffar A, Renvert S (2004) Effect of oxybenzone on PGE2-production in vitro and on plaque and gingivitis in vivo. J Clin Periodontol 31:91-94
26. Kerdvongbundit V, Wikesjo UM (2003) Effect of triclosan on healing following non-surgical periodontal therapy in smokers. J Clin Periodontol 30:1024-1030
27. Kinane DF, Mark Bartold P (2007) Clinical relevance of the host responses of periodontitis. Periodontology 2000 43:278-93
28. Kinane DF, Shiba H, Stathopoulou PG, Zhao H, Lappin DF, Singh A, Eskan MA, Beckers S, Waigel S, Alpert B, Knudsen TB (2006) Gingival epithelial cells heterozygous for Toll-like receptor 4 polymorphisms Asp299Gly and Thr399ile are hypo-responsive to Porphyromonas gingivalis. Genes Immun 7:190-200
29. Labro MT (2000) Interference of antibacterial agents with phagocyte functions: Immunomodulation or "immuno-fairy tales"? Clin Microbiol Rev 13:615-650
30. Labro MT (2005) Anti-inflammatory activity of ansamycins. Expert Rev Anti Infect Ther 3:91-103
31. Leyden JJ (2003) A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol 49(3 Suppl):S200-S210
32. Lin YJ, Fung KK, Kong BM, DeSalva SJ (1994) Gingival absorption of triclosan following topical mouthrinse application. Am J of Dent 7:13-16
33. Lindhe J, Hamp S, Löe H (1973) Experimental periodontitis in the beagle dog. J Periodontol Res 8:1-10
34. Löe H, Theilade E, Jensen SB (1965) Experimental gingivitis in man. J Clin Periodontol 36:177-187
35. Mai V, Morris JG Jr (2004) Colonic bacterial flora: Changing understandings in the molecular age. J Nutr 134:459-464
36. Monack DM, Mueller A, Falkow S (2004) Persistent bacterial infections: the interface of the pathogen and the host immune system. Nat Rev Microbiol 2:747-765
37. Modeer T, Bengtsson A, Rolla G (1996) Triclosan reduces prostaglandin biosynthesis in human gingival fibroblasts challenged with interleukin-1 in vitro. J Clin Periodontol 23:927-933
38. Mori Y, Yoshimura A, Ukai T, Lien E, Espevik T, Hara Y (2003) Immunohistochemical localization of Toll-like receptors 2 and 4 in gingival tissue from patients with periodontitis. Oral Microbiol Immunol 18:54-58
39. Mustafa M, Bakhiet M, Wondimu B, Modeer T (2000) Effect of triclosan on interferon-gamma production and major histocompatibility complex class II expression in human gingival fibroblasts. J Clin Periodontol 27:733-737
40. Mustafa M, Wondimu B, Yucel-Lindberg T, Kats-Hallstrom AT, Jonsson AS, Modeer T (2005) Triclosan reduces microsomal prostaglandin E synthase-1 expression in human gingival fibroblasts. J Clin Periodontol 32:6-11
41. Muthukuru M, Jotwani R, Cutler CW (2005) Oral mucosal endotoxin tolerance induction in chronic periodontitis. Infect Immun 73:687-694
42. Nathan C (2002) Points of control in inflammation. Nature 420:846-852
43. Oguz H, Oguz E, Karadede S (2000) Effect of taurolidine on the normal eyelid and conjunctival flora. Curr Eye Res 21:851-855
44. Oliver RC, Brown LJ, Löe H (1998) Periodontal diseases in the United States population. J Periodontol 69:269-278
45. Palazzi C, Olivieri I, D'Amico E, Pennese E, Petricca A (2004) Management of reactive arthritis. Exp Opin Pharmacother 5:61-70
46. Paraskevas S (2005) Randomized controlled clinical trials on agents used for chemical plaque control. Int J Dent Hyg 3:162-178
47. Peterson JT (2004) Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Failure Rev 9:63-79
48. Ramberg P, Furuichi Y, Sherl D, Volpe AR, Nabi N, Gaffar A, Lindhe J (1995) The effect of triclosan on developing gingivitis. J Clin Periodontol 22:442-448
49. Reynolds S, Moran J, Wade WG, Addy M, Newcombe R (1991) Taurolin as an oral rinse. II. Effects on in vitro and in vivo plaque regrowth. Clin Prevent Dent 13:18-22
50. Rokita JR, Hazen SP, Millen D, Volpe AR (1975) An in vivo study of an antimicrobial mouth rinse on supragingival and subgingival plaque and calculus formation. Pharmacol Ther Dentist 2:1-11
51. Rosling B, Dahlen G, Volpe A, Furuichi Y, Ramberg P, Lindhe J (1997) The use of a triclosan/copolymer dentifrice may retard the progression of periodontitis. J Clin Periodontol 24:873-880
52. Sahingur SE, Cohen RE (2004) Analysis of host responses and risk for disease progression. Periodontol 2000 34:57-83
53. Sapadin AN, Fleischmajer R (2006) Tetracyclines: Nonantibiotic properties and their clinical implications. J Am Acad Dermatol 54:258-265
54. Schroder NW, Schumann RR (2005) Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 5:156-164
55. Schroder NW, Meister D, Wolff V, Christan C, Kaner D, Haban V, Purucker P, Hermann C, Moter A, Gobel UB, Schumann RR (2005) Chronic periodontal disease is associated with single-nucleotide polymorphisms of the human TLR-4 gene. Genes Immun and Immunity 6:448-451
56. Schuller-Levis GB, Park E (2003) Taurine: New implications for an old amino acid. FEMS Microbiol Lett 226:195-202
57. Sekino S, Ramberg P (2005) The effect of a mouth rinse containing phenolic compounds on plaque formation and developing gingivitis. J Clin Periodontol 32:1083-1088
58. Shapiro S, Guggenheim B (1998) Inhibition of oral bacteria by phenolic compounds. Part I. QSAR analysis using molecular connectivity. Quant Struct Activity Relationships 17:327-337
59. Skaare A, Eide G, Herlofson B, Barkvoll P (1996) The effect of toothpaste containing triclosan on oral mucosal desquamation. A model study. J Clin Periodontol 23:1100-1103
60. Skaare AB, Kjaerheim V, Barkvoll P, Rolla G (1997) Does the nature of the solvent affect the anti-inflammatory capacity of triclosan? An experimental study. J Clin Periodontol 24:124-128
61. Skidmore R, Kovach R, Walker C, Thomas J, Bradshaw M, Leyden J, Powala C, Ashley R (2003) Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 139:459-464
62. Socransky SS, Haffajee AD (2002) Dental biofilms: Difficult therapeutic targets. Periodontology 2000 28:12-55
63. Tlaskalova-Hogenova H, Stepankova R, Hudcovic T, Tuckova L, Cukrowska B, Lodinova-Zadnikova R, Kozakova H, Rossmann P, Bartova J, Sokol D, Funda DP, Borovska D, Rehakova Z, Sinkora J, Hofman J, Drastich P, Kokesova A (2004) Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett 93:97-108
64. U.S. Department of Health and Human Services (2000) Oral health in America: A report of the Surgeon-Genera. U.S. Department of Health and Human Services, National Institute of Dental and Craniofacial Research, National Institutes of Health, Rockville, MD
65. Volpe AR, Petrone ME, De Vizio W, Davies RM, Proskin HM (1996) A review of plaque, gingivitis, calculus and caries clinical efficacy studies with a fluoride dentifrice containing triclosan and PVM/MA copolymer. J Clin Dent 7(Suppl):S1-S14
66. Waaler SM, Rolla G, Skjorland KK, Ogaard B (1993) Effects of oral rinsing with triclosan and sodium lauryl sulfate on dental plaque formation: A pilot study. Scand J Dent Res 101:192-195
67. Wang PL, Ohura K, Fujii T, Oido-Mori M, Kowashi Y, Kikuchi M, Suetsugu Y, Tanaka J (2003) DNA microarray analysis of human gingival fibroblasts from healthy and inflammatory gingival tissues. Biochem Biophys Res Comm 305:970-973
68. Ulevitch RJ (2004) Therapeutics targeting the innate immune system. Nat Rev Immunol 4:512-520
69. Zimmermann M, Preac-Mursic V (1992) In vitro activity of taurolidine, chlorophenol-camphor-menthol and chlorhexidine against oral pathogenic microorganisms. Arzneimittelforschung 42:1157-1159
70. Zoetendal EG, Collier CT, Koike S, Mackie RI, Gaskins HR (2004) Molecular ecological analysis of the gastrointestinal microbiota: A review. J Nutr 134:465-472